Identifying clusters of coexisting conditions and outcomes among adults admitted to hospital with community-acquired pneumonia: a multicentre cohort study.

CMAJ open Pub Date : 2023-09-01 DOI:10.9778/cmajo.20220193
Sarah L Malecki, Hae Young Jung, Anne Loffler, Mark A Green, Samir Gupta, Derek MacFadden, Nick Daneman, Ross Upshur, Michael Fralick, Lauren Lapointe-Shaw, Terence Tang, Adina Weinerman, Janice L Kwan, Jessica J Liu, Fahad Razak, Amol A Verma
{"title":"Identifying clusters of coexisting conditions and outcomes among adults admitted to hospital with community-acquired pneumonia: a multicentre cohort study.","authors":"Sarah L Malecki,&nbsp;Hae Young Jung,&nbsp;Anne Loffler,&nbsp;Mark A Green,&nbsp;Samir Gupta,&nbsp;Derek MacFadden,&nbsp;Nick Daneman,&nbsp;Ross Upshur,&nbsp;Michael Fralick,&nbsp;Lauren Lapointe-Shaw,&nbsp;Terence Tang,&nbsp;Adina Weinerman,&nbsp;Janice L Kwan,&nbsp;Jessica J Liu,&nbsp;Fahad Razak,&nbsp;Amol A Verma","doi":"10.9778/cmajo.20220193","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Little is known about patterns of coexisting conditions and their influence on clinical care or outcomes in adults admitted to hospital for community-acquired pneumonia (CAP). We sought to evaluate how coexisting conditions cluster in this population to advance understanding of how multimorbidity affects CAP.</p><p><strong>Methods: </strong>We studied 11 085 adults admitted to hospital with CAP at 7 hospitals in Ontario, Canada. Using cluster analysis, we identified patient subgroups based on clustering of comorbidities in the Charlson Comorbidity Index. We derived and replicated cluster analyses in independent cohorts (derivation sample 2010-2015, replication sample 2015-2017), then combined these into a total cohort for final cluster analyses. We described differences in medications, imaging and outcomes.</p><p><strong>Results: </strong>Patients clustered into 7 subgroups. The low comorbidity subgroup (<i>n</i> = 3052, 27.5%) had no comorbidities. The DM-HF-Pulm subgroup had prevalent diabetes, heart failure and chronic lung disease (<i>n</i> = 1710, 15.4%). One disease category defined each remaining subgroup, as follows: pulmonary (<i>n</i> = 1621, 14.6%), diabetes (<i>n</i> = 1281, 11.6%), heart failure (<i>n</i> = 1370, 12.4%), dementia (<i>n</i> = 1038, 9.4%) and cancer (<i>n</i> = 1013, 9.1%). Corticosteroid use ranged from 11.5% to 64.9% in the dementia and pulmonary subgroups, respectively. Piperacillin-tazobactam use ranged from 9.1% to 28.0% in the pulmonary and cancer subgroups, respectively. The use of thoracic computed tomography ranged from 5.7% to 36.3% in the dementia and cancer subgroups, respectively. Adjusting for patient factors, the risk of in-hospital death was greater in the cancer (adjusted odds ratio [OR] 3.12, 95% confidence interval [CI] 2.44-3.99), dementia (adjusted OR 1.57, 95% CI 1.05-2.35), heart failure (adjusted OR 1.66, 95% CI 1.35-2.03) and DM-HF-Pulm subgroups (adjusted OR 1.35, 95% CI 1.12-1.61), and lower in the diabetes subgroup (adjusted OR 0.67, 95% CI 0.50-0.89), compared with the low comorbidity group.</p><p><strong>Interpretation: </strong>Patients admitted to hospital with CAP cluster into clinically recognizable subgroups based on coexisting conditions. Clinical care and outcomes vary among these subgroups with little evidence to guide decision-making, highlighting opportunities for research to personalize care.</p>","PeriodicalId":10432,"journal":{"name":"CMAJ open","volume":"11 5","pages":"E799-E808"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/fd/cmajo.20220193.PMC10482492.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CMAJ open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9778/cmajo.20220193","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Little is known about patterns of coexisting conditions and their influence on clinical care or outcomes in adults admitted to hospital for community-acquired pneumonia (CAP). We sought to evaluate how coexisting conditions cluster in this population to advance understanding of how multimorbidity affects CAP.

Methods: We studied 11 085 adults admitted to hospital with CAP at 7 hospitals in Ontario, Canada. Using cluster analysis, we identified patient subgroups based on clustering of comorbidities in the Charlson Comorbidity Index. We derived and replicated cluster analyses in independent cohorts (derivation sample 2010-2015, replication sample 2015-2017), then combined these into a total cohort for final cluster analyses. We described differences in medications, imaging and outcomes.

Results: Patients clustered into 7 subgroups. The low comorbidity subgroup (n = 3052, 27.5%) had no comorbidities. The DM-HF-Pulm subgroup had prevalent diabetes, heart failure and chronic lung disease (n = 1710, 15.4%). One disease category defined each remaining subgroup, as follows: pulmonary (n = 1621, 14.6%), diabetes (n = 1281, 11.6%), heart failure (n = 1370, 12.4%), dementia (n = 1038, 9.4%) and cancer (n = 1013, 9.1%). Corticosteroid use ranged from 11.5% to 64.9% in the dementia and pulmonary subgroups, respectively. Piperacillin-tazobactam use ranged from 9.1% to 28.0% in the pulmonary and cancer subgroups, respectively. The use of thoracic computed tomography ranged from 5.7% to 36.3% in the dementia and cancer subgroups, respectively. Adjusting for patient factors, the risk of in-hospital death was greater in the cancer (adjusted odds ratio [OR] 3.12, 95% confidence interval [CI] 2.44-3.99), dementia (adjusted OR 1.57, 95% CI 1.05-2.35), heart failure (adjusted OR 1.66, 95% CI 1.35-2.03) and DM-HF-Pulm subgroups (adjusted OR 1.35, 95% CI 1.12-1.61), and lower in the diabetes subgroup (adjusted OR 0.67, 95% CI 0.50-0.89), compared with the low comorbidity group.

Interpretation: Patients admitted to hospital with CAP cluster into clinically recognizable subgroups based on coexisting conditions. Clinical care and outcomes vary among these subgroups with little evidence to guide decision-making, highlighting opportunities for research to personalize care.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一项多中心队列研究:在社区获得性肺炎住院的成人中识别共存的条件和结局。
背景:对于因社区获得性肺炎(CAP)住院的成人患者的共存疾病模式及其对临床护理或预后的影响知之甚少。我们试图评估共存疾病如何在这一人群中聚集,以促进对多病如何影响CAP的理解。方法:我们研究了加拿大安大略省7家医院的11085名CAP患者。通过聚类分析,我们根据Charlson合并症指数中的合并症聚类来确定患者亚组。我们在独立队列中推导和重复聚类分析(推导样本2010-2015,复制样本2015-2017),然后将这些组合成一个总队列进行最终的聚类分析。我们描述了在药物、影像和结果方面的差异。结果:患者可分为7个亚组。低合并症亚组(n = 3052, 27.5%)无合并症。DM-HF-Pulm亚组患者普遍患有糖尿病、心力衰竭和慢性肺部疾病(n = 1710, 15.4%)。每个剩余的亚组定义一个疾病类别,如下:肺病(n = 1621, 14.6%)、糖尿病(n = 1281, 11.6%)、心力衰竭(n = 1370, 12.4%)、痴呆(n = 1038, 9.4%)和癌症(n = 1013, 9.1%)。在痴呆和肺亚组中,皮质类固醇的使用范围分别为11.5%至64.9%。哌拉西林-他唑巴坦在肺亚组和癌症亚组的使用率分别为9.1%至28.0%。在痴呆和癌症亚组中,胸部计算机断层扫描的使用率分别为5.7%至36.3%。调整患者因素后,与低合并症组相比,癌症(校正比值比[OR] 3.12, 95%可信区间[CI] 2.44-3.99)、痴呆(校正比值比[OR] 1.57, 95% CI 1.05-2.35)、心力衰竭(校正比值比[OR] 1.66, 95% CI 1.35-2.03)和DM-HF-Pulm亚组(校正比值比[OR] 1.35, 95% CI 1.12-1.61)的住院死亡风险更高,糖尿病亚组(校正比值比[OR] 0.67, 95% CI 0.50-0.89)的住院死亡风险更低。解释:住院的CAP患者根据共存情况分为临床可识别的亚组。这些亚组的临床护理和结果各不相同,指导决策的证据很少,这突出了个性化护理研究的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Validity of diagnoses of SARS-CoV-2 infection in Canadian administrative health data: a multiprovince, population-based cohort study. Trends in attachment to a primary care provider in Ontario, 2008-2018: an interrupted time-series analysis. Identifying clusters of coexisting conditions and outcomes among adults admitted to hospital with community-acquired pneumonia: a multicentre cohort study. Is the number of ideal cardiovascular health metrics in midlife associated with lower risk of cancer? Evidence from 3 European prospective cohorts. Trends in antihypertensive drug utilization in British Columbia, 2004-2019: a descriptive study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1